MitoSense began with the work of Dr. Robert Elliott, MD, PhD.
We continue to build upon his foundation to help millions of people overcome disease.
MitoSense, Inc. is a research and development company in the field of securing development of treatments for neurodegenerative diseases. With exclusively licensed technology to replenish the mitochondria in humans using Mitochondria Organelle Transplantation (MOT™️), the company, through its U.S. based research partner is initially focusing its efforts on treating ALS. MOT™️ may impact research for patients with Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative diseases, none of which have a cure.
MitoSense uses a proprietary (patent pending) technique to replenish mitochondria to treat ALS. The technique has the potential to treat a wide range of indications including Alzheimer’s, Parkinson’s, Huntington’s, Multiple Sclerosis and other neurodegenerative diseases. With experienced leadership in business, government, research, and medical, we have brought together a multidisciplinary team to help in the fight.
Our team approach brings the distinct possibility of improving conditions in ALS patients and those with other neurodegenerative diseases. MitoSense began with the work of Dr. Robert Elliott, MD, PhD and continues in his memoriam.
Dr. Robert Elliott, MD, PhD
Dr. Elliott, along with MitoSense's Xian Peng Jiang, first conceptualized our MOT™️ technology in their 2012 paper, which explored introducing mitochondria into cancer cells to restore mitochondrial function and inhibit cancer cell growth.
Before his breakthrough work on mitochondrial dysfunction, Dr. Elliott had a long and distinguished career researching and innovating cancer treatments with an emphasis on immunology. He helped countless patients with their battles against cancer. He established the Sallie Astor Burdine Breast Foundation and the Elliott Mitochondria Research Center. You can learn about their work and donate to the foundation here.
You can also read more about his life and career in this Newsmax op-ed.
On the right, he's pictured with former U.S. Secretary of Health & Human Services (HHS) Tom Price at HHS headquarters following a briefing on his latest research.